Martingale Asset Management L P Buys 4,761 Shares of ICU Medical, Inc. $ICUI

Key Points

• Martingale Asset Management L P has increased its stake in ICU Medical by 28.3%, acquiring an additional 4,761 shares, bringing its total holdings to 21,561 shares worth approximately $2.99 million.
• ICU Medical reported a quarterly earnings per share of $2.10, surpassing analyst expectations, and projected a full-year earnings guidance of 6.850-7.15 EPS for FY 2025.
• Institutional investors own approximately 96.10% of ICU Medical shares, reflecting strong institutional interest in the company.

Martingale Asset Management L P increased its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 28.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,561 shares of the medical instruments supplier's stock after purchasing an additional 4,761 shares during the period. Martingale Asset Management L P owned approximately 0.09% of ICU Medical worth $2,994,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its position in shares of ICU Medical by 18.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier's stock worth $83,788,000 after purchasing an additional 82,982 shares during the last quarter. Northern Trust Corp increased its position in shares of ICU Medical by 11.1% in the fourth quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier's stock worth $62,431,000 after purchasing an additional 40,187 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of ICU Medical by 63.2% in the fourth quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier's stock worth $38,069,000 after purchasing an additional 95,030 shares during the last quarter. Invesco Ltd. increased its position in shares of ICU Medical by 80.1% in the first quarter. Invesco Ltd. now owns 203,827 shares of the medical instruments supplier's stock worth $28,303,000 after purchasing an additional 90,674 shares during the last quarter. Finally, Oberweis Asset Management Inc. boosted its stake in ICU Medical by 20.1% in the fourth quarter. Oberweis Asset Management Inc. now owns 156,680 shares of the medical instruments supplier's stock worth $24,312,000 after buying an additional 26,180 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Stock Performance

NASDAQ:ICUI opened at $121.75 on Friday. The firm has a market cap of $3.01 billion, a PE ratio of -80.10 and a beta of 0.88. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $196.26. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. The business has a 50 day moving average price of $127.24 and a 200-day moving average price of $137.28.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. The firm had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The business's quarterly revenue was down 8.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities research analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on ICUI shares. Raymond James Financial cut their target price on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research note on Friday, August 8th. Piper Sandler started coverage on ICU Medical in a research note on Friday, August 15th. They issued an "overweight" rating and a $145.00 target price for the company. Finally, Wall Street Zen lowered ICU Medical from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $179.00.

Insider Buying and Selling

In other ICU Medical news, CEO Vivek Jain bought 21,929 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The stock was bought at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the completion of the acquisition, the chief executive officer directly owned 130,149 shares in the company, valued at $14,686,013.16. The trade was a 20.26% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Christian B. Voigtlander sold 4,985 shares of the company's stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $128.50, for a total value of $640,572.50. Following the transaction, the chief operating officer owned 6,088 shares of the company's stock, valued at approximately $782,308. This represents a 45.02% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.